161 related articles for article (PubMed ID: 16698271)
1. Novel benzofuran inhibitors of human mitogen-activated protein kinase phosphatase-1.
Lazo JS; Nunes R; Skoko JJ; Queiroz de Oliveira PE; Vogt A; Wipf P
Bioorg Med Chem; 2006 Aug; 14(16):5643-50. PubMed ID: 16698271
[TBL] [Abstract][Full Text] [Related]
2. The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1.
Vogt A; Tamewitz A; Skoko J; Sikorski RP; Giuliano KA; Lazo JS
J Biol Chem; 2005 May; 280(19):19078-86. PubMed ID: 15753082
[TBL] [Abstract][Full Text] [Related]
3. Structurally unique inhibitors of human mitogen-activated protein kinase phosphatase-1 identified in a pyrrole carboxamide library.
Lazo JS; Skoko JJ; Werner S; Mitasev B; Bakan A; Koizumi F; Yellow-Duke A; Bahar I; Brummond KM
J Pharmacol Exp Ther; 2007 Sep; 322(3):940-7. PubMed ID: 17538006
[TBL] [Abstract][Full Text] [Related]
4. Cell-active dual specificity phosphatase inhibitors identified by high-content screening.
Vogt A; Cooley KA; Brisson M; Tarpley MG; Wipf P; Lazo JS
Chem Biol; 2003 Aug; 10(8):733-42. PubMed ID: 12954332
[TBL] [Abstract][Full Text] [Related]
5. Dipyridamole activation of mitogen-activated protein kinase phosphatase-1 mediates inhibition of lipopolysaccharide-induced cyclooxygenase-2 expression in RAW 264.7 cells.
Chen TH; Kao YC; Chen BC; Chen CH; Chan P; Lee HM
Eur J Pharmacol; 2006 Jul; 541(3):138-46. PubMed ID: 16765938
[TBL] [Abstract][Full Text] [Related]
6. Compartment-specific regulation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) mitogen-activated protein kinases (MAPKs) by ERK-dependent and non-ERK-dependent inductions of MAPK phosphatase (MKP)-3 and MKP-1 in differentiating P19 cells.
Reffas S; Schlegel W
Biochem J; 2000 Dec; 352 Pt 3(Pt 3):701-8. PubMed ID: 11104676
[TBL] [Abstract][Full Text] [Related]
7. Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors.
Johnston PA; Foster CA; Shun TY; Skoko JJ; Shinde S; Wipf P; Lazo JS
Assay Drug Dev Technol; 2007 Jun; 5(3):319-32. PubMed ID: 17638532
[TBL] [Abstract][Full Text] [Related]
8. Regulation of c-Jun N-terminal kinase and p38 kinase pathways in endothelial cells.
Wadgaonkar R; Pierce JW; Somnay K; Damico RL; Crow MT; Collins T; Garcia JG
Am J Respir Cell Mol Biol; 2004 Oct; 31(4):423-31. PubMed ID: 15231489
[TBL] [Abstract][Full Text] [Related]
9. ERK1/2-driven and MKP-mediated inhibition of EGF-induced ERK5 signaling in human proximal tubular cells.
Sarközi R; Miller B; Pollack V; Feifel E; Mayer G; Sorokin A; Schramek H
J Cell Physiol; 2007 Apr; 211(1):88-100. PubMed ID: 17131384
[TBL] [Abstract][Full Text] [Related]
10. Hyperosmotic induction of the mitogen-activated protein kinase phosphatase MKP-1 in H4IIE rat hepatoma cells.
Schliess F; Heinrich S; Häussinger D
Arch Biochem Biophys; 1998 Mar; 351(1):35-40. PubMed ID: 9500841
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of mitogen-activated protein kinase inhibition by parathyroid hormone in osteoblast-like cells.
Hömme M; Schmitt CP; Mehls O; Schaefer F
J Am Soc Nephrol; 2004 Nov; 15(11):2844-50. PubMed ID: 15504937
[TBL] [Abstract][Full Text] [Related]
12. Mitogen-activated protein kinase (MAPK) phosphatase-1 and -4 attenuate p38 MAPK during dexamethasone-induced insulin resistance in 3T3-L1 adipocytes.
Bazuine M; Carlotti F; Tafrechi RS; Hoeben RC; Maassen JA
Mol Endocrinol; 2004 Jul; 18(7):1697-707. PubMed ID: 15184525
[TBL] [Abstract][Full Text] [Related]
13. Catalytic activation of mitogen-activated protein (MAP) kinase phosphatase-1 by binding to p38 MAP kinase: critical role of the p38 C-terminal domain in its negative regulation.
Hutter D; Chen P; Barnes J; Liu Y
Biochem J; 2000 Nov; 352 Pt 1(Pt 1):155-63. PubMed ID: 11062068
[TBL] [Abstract][Full Text] [Related]
14. Cell-active dual specificity phosphatase inhibitors identified by high-content screening.
Vogt A; Cooley KA; Brisson M; Tarpley MG; Wipf P; Lazo JS
Drug Discov Today; 2005; Suppl():3-12. PubMed ID: 23570161
[TBL] [Abstract][Full Text] [Related]
15. Expression, purification, and enzymatic characterization of the dual specificity mitogen-activated protein kinase phosphatase, MKP-4.
Hong SB; Lubben TH; Dolliver CM; Petrolonis AJ; Roy RA; Li Z; Parsons TF; Li P; Xu H; Reilly RM; Trevillyan JM; Nichols AJ; Tummino PJ; Gant TG
Bioorg Chem; 2005 Feb; 33(1):34-44. PubMed ID: 15668181
[TBL] [Abstract][Full Text] [Related]
16. Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.
Johnston PA; Foster CA; Tierno MB; Shun TY; Shinde SN; Paquette WD; Brummond KM; Wipf P; Lazo JS
Assay Drug Dev Technol; 2009 Jun; 7(3):250-65. PubMed ID: 19530895
[TBL] [Abstract][Full Text] [Related]
17. Novel hydroxyl naphthoquinones with potent Cdc25 antagonizing and growth inhibitory properties.
Peyregne VP; Kar S; Ham SW; Wang M; Wang Z; Carr BI
Mol Cancer Ther; 2005 Apr; 4(4):595-602. PubMed ID: 15827333
[TBL] [Abstract][Full Text] [Related]
18. Feedback control of MKP-1 expression by p38.
Hu JH; Chen T; Zhuang ZH; Kong L; Yu MC; Liu Y; Zang JW; Ge BX
Cell Signal; 2007 Feb; 19(2):393-400. PubMed ID: 16978838
[TBL] [Abstract][Full Text] [Related]
19. Adrenocorticotropin induces mitogen-activated protein kinase phosphatase 1 in Y1 mouse adrenocortical tumor cells.
Bey P; Gorostizaga AB; Maloberti PM; Lozano RC; Poderoso C; Cornejo Maciel F; Podestá EJ; Paz C
Endocrinology; 2003 Apr; 144(4):1399-406. PubMed ID: 12639923
[TBL] [Abstract][Full Text] [Related]
20. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance.
Small GW; Shi YY; Higgins LS; Orlowski RZ
Cancer Res; 2007 May; 67(9):4459-66. PubMed ID: 17483361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
